Bibliography
- Bugianesi E , McCulloughAJ, MarchesiniG: Insulin resistance: a metabolic pathway to chronic liver disease.Hepatology42, 987–1000 (2005).
- Brunt EM , JanneyCG, DiBisceglieAMet al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.Am. J. Gastroenterol.94, 2467–2474 (1999).
- Guha IN , ParkesJ, RoderickPRet al.: Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.Gut55, 1650–1660 (2006).
- Marchesini G , BugianesiE, ForlaniGet al.: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.Hepatology37, 917–923 (2003).
- Teli MR , JamesOFW, BurtDet al.: The natural history of nonalcoholic fatty liver: a follow-up study.Hepatology22, 1714–1719 (1995).
- Ratziu V , GiralP, CharlotteFet al.: Liver fibrosis in overweight patients.Gastroenterology118, 1117–1123 (2000).
- Adams LA , LympJF, St Sauver J et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology129, 113–121 (2005).
- Matteoni CA , YounossiZM, GramlichTet al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.Gastroenterology116, 1413–1419 (1999).
- Ratziu V , CharlotteF, HeurtierAet al.: Sampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology128, 1898–1906 (2005).
- Dam-Larsen S , FranzmannM, AndersenIBet al.: Long term prognosis of fatty liver: risk of chronic liver disease and death.Gut53, 750–755 (2004).
- Jepsen P , VilstrupH, MellemkjaerLet al.: Prognosis of patients with a diagnosis of fatty liver – a registry-based cohort study.Hepatogastroenterology50, 2101–2104 (2003).
- Ekstedt M , FranzenLE, MathiesenULet al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes.Hepatology44, 865–873 (2006).
- Kleiner DE , BruntEM, Van Natta M et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology41, 1313–1321 (2005).
- Younossi ZM , GramlichT, LiuYCet al.: Non-alcoholic fatty liver disease: assessment of variability in pathologic interpretations.Mod. Pathol.11, 560–565 (1998).
- Dixon JB , BhathalPS, O‘BrienPE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.Gastroenterology121, 91–100 (2001).
- Campos GM , BambhaK, VittinghoffEet al.: A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients.Hepatology47, 1916–1923 (2008).
- Ong JP , ElarinyH, CollantesRet al.: Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes. Surg.15, 310–315 (2005).
- Beymer C , KowdleyKV, LarsonAet al.: Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery.Arch. Surg.138, 1240–1244 (2003).
- Solga SF , ClarkJM, AlkhuraishiARet al.: Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients.Surg. Obes. Relat. Dis.1, 6–11 (2005).
- Boza C , RiquelmeA, IbanezLet al.: Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.Obes. Surg.15, 1148–1153 (2005).
- Harnois F , MsikaS, SabateJMet al.: Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.Obes. Surg.16, 183–188 (2006).
- Haukeland JW , KonopskiZ, LinnestadPet al.: Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.Scand. J. Gastroenterol.40, 1469–1477 (2005).
- Hui JM , HodgeA, FarrellGCet al.: Beyond insulin resistance in NASH: TNF-α or adiponectin?Hepatology40, 46–54 (2004).
- Musso G , GambinoR, DurazzoMet al.: Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.Hepatology42, 1175–1183 (2005).
- Targher G , BertoliniL, RodellaSet al.: Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.Clin. Endocrinol. (Oxf.)64, 679–683 (2006).
- Bugianesi E , PagottoU, ManiniRet al.: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.J. Clin. Endocrinol. Metab.90, 3498–3504 (2005).
- Palekar NA , NausR, LarsonSPet al.: Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.Liver Int.26, 151–156 (2006).
- Xu A , WangY, KeshawHet al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.J. Clin. Invest.112, 91–100 (2003).
- Lemoine M , RatziuV, MaachiMet al.: Serum adipokine levels predictive of liver injury in patients with non-alcoholic fatty liver disease.J. Hepatol.42, 24A (2005).
- Wong VW , HuiAY, TsangSWet al.: Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.Clin. Gastroenterol. Hepatol.4, 1154–1161 (2006).
- Papadia FS , MarinariGM, CameriniGet al.: Liver damage in severely obese patients: a clinical–biochemical–morphologic study on 1,000 liver biopsies.Obes. Surg.14, 952–958 (2004).
- Sakugawa H , NakayoshiT, KobashigawaKet al.: Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.World J. Gastroenterol.11, 255–259 (2005).
- Portincasa P , GrattaglianoI, LauterburgBHet al.: Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis.Clin. Sci.111, 135–143 (2006).
- Solga SF , AlkhuraisheA, CopeKet al.: Breath biomarkers and non-alcoholic fatty liver disease: preliminary observations.Biomarkers11, 174–183 (2006).
- Yoneda M , MawatariH, FujitaKet al.: High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH.J. Gastroenterol.42, 573–582 (2007).
- Anty R , BekriS, LucianiNet al.: The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH.Am. J. Gastroenterol.101, 1824–1833 (2006).
- Day CP : Pathogenesis of steatohepatitis.Best Pract. Res. Clin. Gastroenterol.16, 663–678 (2002).
- Chalasani N , DeegMA, CrabbDW: Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.Am. J. Gastroenterol.99, 1497–1502 (2004).
- Bonnefont-Rousselot D , RatziuV, GiralPet al.: Blood oxidative stress markers are unreliable markers of hepatic steatosis.Aliment. Pharmacol. Ther.23, 91–98 (2006).
- Yesilova Z , YamanH, OktenliCet al.: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease.Am. J. Gastroenterol.100, 850–855 (2005).
- Machado MV , RavascoP, JesusLet al.: Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet.Scand. J. Gastroenterol.43, 95–102 (2008).
- Yoneda M , UchiyamaT, KatoSet al.: Plasma pentraxin 3 is a novel marker for nonalcoholic steatohepatitis (NASH).BMC Gastroenterol.8, 53 (2008).
- Sumida Y , NakashimaT, YohTet al.: Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease.J. Hepatol.38, 32–38 (2003).
- Shimada M , KawaharaH, OzakiKet al.: Usefulness of a combined evaluation of the serum adiponectin level, HOMIR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis.Am. J. Gastroenterol.102, 1931–1938 (2007).
- Yilmaz Y , UlukayaE, GulOOet al.: Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.Clin. Biochem.42, 802–807 (2009).
- Poynard T , Imbert-BismutF, MunteanuMet al.: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C.Comp. Hepatol.3, 8 (2004).
- Poynard T , MunteanuM, Imbert-BismutFet al.: Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C.Clin. Chem.50, 1344–1355 (2004).
- Rosenberg WM , VoelkerM, ThielRet al.: Serum markers detect the presence of liver fibrosis: a cohort study.Gastroenterology127, 1704–1713 (2004).
- Cales P , ObertiF, MichalakSet al.: A novel panel of blood markers to assess the degree of liver fibrosis.Hepatology42, 1373–1381 (2005).
- Poynard T , RatziuV, CharlotteFet al.: Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.BMC Gastroenterol.6, 34 (2006).
- de Ledinghen V , RatziuV, CausseXet al.: Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study.J. Hepatol.45, 592–599 (2006).
- Omary MB , KuNO, ToivolaDM: Keratins: guardians of the liver.Hepatology35, 251–257 (2002).
- Feldstein AE , CanbayA, AnguloPet al.: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.Gastroenterology125, 437–443 (2003).
- Wieckowska A , ZeinNN, YerianLMet al.: In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.Hepatology44, 27–33 (2006).
- Mitry RR , De Bruyne R, Quaglia A et al.: Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers. Hepatology46, 2047–2048; author reply 2048 (2007).
- Yilmaz Y , DolarE, UlukayaEet al.: Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.World J. Gastroenterol.13, 837–844 (2007).
- Diab DL , YerianL, SchauerPet al.: Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.Clin. Gastroenterol. Hepatol.6, 1249–1254 (2008).
- Younossi ZM , JarrarM, NugentCet al.: A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).Obes. Surg.18, 1430–1437 (2008).
- Tarantino G , ConcaP, CoppolaAet al.: Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis.Eur. J. Clin. Invest.37, 48–53 (2007).
- Yki-Jarvinen H : Fat in the liver and insulin resistance.Ann. Med.37, 347–356 (2005).
- Belfort R , HarrisonSA, BrownKet al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.N. Engl. J. Med.355, 2297–2307 (2006).
- Ratziu V , GiralP, JacqueminetSet al.: Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial.Gastroenterology135, 100–110 (2008).
- Aithal GP , ThomasJA, KayePVet al.: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.Gastroenterology135, 1176–1184 (2008).
- Trak-Smayra V , DargereD, NounRet al.: Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery.Gut58, 825–832 (2009).
- Morra R , MunteanuM, BedossaPet al.: Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.Aliment. Pharmacol. Ther.26, 847–858 (2007).